Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 19/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 14/20 | 0.55 |
| ▸ | HTR2A | P28223 | 12/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30435034 | 1.00 | SLC6A4 (0.57) | SLC6A4SLC6A2SLC6A3KCNH2HTR2A | |
| SCHEMBL12964268 | 0.83 | SLC6A4 (0.59) | SLC6A4SLC6A2SLC6A3KCNH2HTR2A | |
| SCHEMBL15093979 | 0.82 | CYP3A4 (0.48) | SLC6A4SLC6A2SLC6A3KCNH2HTR2A | |
| SCHEMBL29875226 | 0.81 | SLC6A4 (0.56) | SLC6A4SLC6A2SLC6A3KCNH2HTR2A | |
| SCHEMBL2569349 | 0.81 | SLC6A4 (0.56) | SLC6A4SLC6A2SLC6A3KCNH2HTR2A | |
| Hydrochloric Acid SCHEMBL3591332 | 0.79 | HTT (0.59) | SLC6A4SLC6A2SLC6A3KCNH2HTR2A | |
| SCHEMBL1872934 | 0.78 | KDM4E (0.51) | SLC6A4SLC6A2KCNH2HTR2A | |
| SCHEMBL980220 | 0.78 | SLC6A4 (0.53) | SLC6A4SLC6A2SLC6A3KCNH2HTR2A | |
| SCHEMBL16795136 | 0.78 | SLC6A4 (0.53) | SLC6A4SLC6A2SLC6A3KCNH2HTR2A | |
| SCHEMBL13881914 | 0.78 | SLC6A4 (0.58) | SLC6A4SLC6A2SLC6A3KCNH2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| CN-112679427-B | Tetrahydroisoquinoline derivative, preparation method thereof and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-112679427-A | Tetrahydroisoquinoline derivatives, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2021-04-20 | — | — | CN | disclosed |
| US-20090182142-A1 | Aromatic Compound | FURUKUBO SHIGERU | 2009-07-16 | — | — | US | disclosed |
| EP-1995241-A1 | Inhibitors of ion channels | ICAgen, Incorporated (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2005090354-A1 | PYRAZOLO[3,4-b] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182142-A1 | Aromatic Compound | HRH4, CCR4, HRH3 | SLC6A4 1006/4885SLC6A2 3355/4885SLC6A3 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.